Trials / Not Yet Recruiting
Not Yet RecruitingNCT06762327
Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In lung cancer, ensartinib is effective in improving the prognosis of ALK positive /MET exon 14 skipping patients. However, patients with ALK positive /MET14 exon skipping non-lung cancer solid tumors have limited treatment options in the absence of standard treatment. We hope to bring a new effective and safe treatment option to these patients more efficiently.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ensartinib | ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity |
Timeline
- Start date
- 2025-02-28
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
- First posted
- 2025-01-07
- Last updated
- 2025-01-07
Source: ClinicalTrials.gov record NCT06762327. Inclusion in this directory is not an endorsement.